Page last updated: 2024-12-10

2-(4-chlorophenyl)-3-methyl-N-(2-thiazolyl)butanamide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

## 2-(4-chlorophenyl)-3-methyl-N-(2-thiazolyl)butanamide: A Promising Research Target

**2-(4-chlorophenyl)-3-methyl-N-(2-thiazolyl)butanamide** is a synthetic compound with a complex chemical structure. Its importance lies in its potential as a research tool and drug candidate due to its pharmacological properties.

**Here's a breakdown of its potential significance:**

* **Structure:** The compound contains a butanamide backbone, a 4-chlorophenyl substituent, a 2-thiazolyl group, and a methyl group. This specific arrangement of functional groups contributes to its potential biological activity.
* **Pharmacological Activities:** Research suggests that this compound exhibits:
* **Anti-inflammatory properties:** It might inhibit the production of inflammatory mediators, potentially reducing inflammation in various conditions.
* **Antioxidant activity:** It might scavenge free radicals, protecting cells from oxidative damage.
* **Anti-cancer activity:** Some studies indicate that the compound can inhibit the growth of certain cancer cells, possibly by inducing apoptosis (programmed cell death).

**Research Significance:**

* **Drug Development:** The compound's promising pharmacological activities make it a potential drug candidate for conditions like inflammation, oxidative stress-related disorders, and even cancer. Researchers are actively investigating its efficacy and safety in preclinical studies.
* **Understanding Biological Processes:** This compound can serve as a research tool to understand the mechanisms involved in inflammation, oxidative stress, and cancer cell proliferation. Studying its interactions with biological targets can provide insights into these processes.
* **Development of Novel Therapeutics:** Further research might lead to the development of new drugs based on this compound or its derivatives, potentially providing more effective treatments for various diseases.

**Important Note:**

It's crucial to remember that the research on this specific compound is still ongoing, and its potential as a drug or research tool is not yet fully established. More studies are needed to understand its full pharmacological profile, its safety, and its long-term effects.

**In conclusion, 2-(4-chlorophenyl)-3-methyl-N-(2-thiazolyl)butanamide represents a promising research target with potential applications in drug development and understanding fundamental biological processes. Further research is necessary to fully evaluate its therapeutic potential and contribute to the advancement of medical science.**

Cross-References

ID SourceID
PubMed CID4307629
CHEMBL ID610463
CHEBI ID113043
SCHEMBL ID16369644

Synonyms (32)

Synonym
HMS2644I21
ENAMINE_000061
OPREA1_875848
smr000354300
MLS001018069
CHEBI:113043
HMS1394C17
CHEMBL610463 ,
bdbm50305973
2-(4-chlorophenyl)-3-methyl-n-(thiazol-2-yl)butanamide
cid_4307629
AKOS001033996
2-(4-chlorophenyl)-3-methyl-n-(1,3-thiazol-2-yl)butanamide
4-cmtb
gtpl5500
AKOS016375538
300851-67-6
4-chloro-?-(1-methylethyl)-n-2-thiazolylbenzeneacetamide
SR-01000025543-1
sr-01000025543
SCHEMBL16369644
4-chloro-alpha-(1-methylethyl)-n-2-thiazolylbenzeneacetamide
4-cmtb, >=98% (hplc)
Z28173527
BS-16905
Q27073758
EN300-1262807
CS-0027973
HY-P1125
mfcd02666163
4-chloro-alpha-(1-methylethyl)-n-2-thiazolyl-benzeneacetamide
(+/-)-4-cmtb
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
acetamidesCompounds with the general formula RNHC(=O)CH3.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (15)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
glp-1 receptor, partialHomo sapiens (human)Potency10.00000.01846.806014.1254AID624417
TDP1 proteinHomo sapiens (human)Potency20.59620.000811.382244.6684AID686978; AID686979
Smad3Homo sapiens (human)Potency1.99530.00527.809829.0929AID588855
IDH1Homo sapiens (human)Potency9.20000.005210.865235.4813AID686970
chromobox protein homolog 1Homo sapiens (human)Potency89.12510.006026.168889.1251AID540317
nuclear factor erythroid 2-related factor 2 isoform 2Homo sapiens (human)Potency16.36010.00419.984825.9290AID504444
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency89.12510.050127.073689.1251AID588590
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency17.03900.00798.23321,122.0200AID2546; AID2551
VprHuman immunodeficiency virus 1Potency56.23411.584919.626463.0957AID651644
lamin isoform A-delta10Homo sapiens (human)Potency11.22020.891312.067628.1838AID1487
Rap guanine nucleotide exchange factor 4Homo sapiens (human)Potency8.91253.981146.7448112.2020AID720708
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Free fatty acid receptor 2Homo sapiens (human)IC50 (µMol)0.80000.00900.40450.8000AID454554
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
streptokinase A precursorStreptococcus pyogenes M1 GASEC50 (µMol)85.19350.06008.9128130.5170AID1902; AID1914
Estrogen receptorRattus norvegicus (Norway rat)EC50 (µMol)150.00000.006022.3670130.5170AID1914
Estrogen receptor betaRattus norvegicus (Norway rat)EC50 (µMol)150.00000.006022.3670130.5170AID1914
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (26)

Processvia Protein(s)Taxonomy
leukocyte chemotaxis involved in inflammatory responseFree fatty acid receptor 2Homo sapiens (human)
mucosal immune responseFree fatty acid receptor 2Homo sapiens (human)
regulation of acute inflammatory responseFree fatty acid receptor 2Homo sapiens (human)
positive regulation of cytokine production involved in immune responseFree fatty acid receptor 2Homo sapiens (human)
cell surface pattern recognition receptor signaling pathwayFree fatty acid receptor 2Homo sapiens (human)
positive regulation of acute inflammatory response to non-antigenic stimulusFree fatty acid receptor 2Homo sapiens (human)
G protein-coupled receptor signaling pathwayFree fatty acid receptor 2Homo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayFree fatty acid receptor 2Homo sapiens (human)
lipid storageFree fatty acid receptor 2Homo sapiens (human)
positive regulation of insulin secretionFree fatty acid receptor 2Homo sapiens (human)
positive regulation of chemokine productionFree fatty acid receptor 2Homo sapiens (human)
positive regulation of interleukin-8 productionFree fatty acid receptor 2Homo sapiens (human)
glucose homeostasisFree fatty acid receptor 2Homo sapiens (human)
fat cell differentiationFree fatty acid receptor 2Homo sapiens (human)
negative regulation of insulin secretionFree fatty acid receptor 2Homo sapiens (human)
cellular response to fatty acidFree fatty acid receptor 2Homo sapiens (human)
regulation of peptide hormone secretionFree fatty acid receptor 2Homo sapiens (human)
ligand-gated ion channel signaling pathwayFree fatty acid receptor 2Homo sapiens (human)
adaptive immune responseRap guanine nucleotide exchange factor 4Homo sapiens (human)
G protein-coupled receptor signaling pathwayRap guanine nucleotide exchange factor 4Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayRap guanine nucleotide exchange factor 4Homo sapiens (human)
calcium-ion regulated exocytosisRap guanine nucleotide exchange factor 4Homo sapiens (human)
regulation of exocytosisRap guanine nucleotide exchange factor 4Homo sapiens (human)
insulin secretionRap guanine nucleotide exchange factor 4Homo sapiens (human)
positive regulation of insulin secretionRap guanine nucleotide exchange factor 4Homo sapiens (human)
regulation of synaptic vesicle cycleRap guanine nucleotide exchange factor 4Homo sapiens (human)
Ras protein signal transductionRap guanine nucleotide exchange factor 4Homo sapiens (human)
regulation of insulin secretionRap guanine nucleotide exchange factor 4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (7)

Processvia Protein(s)Taxonomy
G protein-coupled receptor activityFree fatty acid receptor 2Homo sapiens (human)
protein bindingFree fatty acid receptor 2Homo sapiens (human)
lipid bindingFree fatty acid receptor 2Homo sapiens (human)
guanyl-nucleotide exchange factor activityRap guanine nucleotide exchange factor 4Homo sapiens (human)
protein bindingRap guanine nucleotide exchange factor 4Homo sapiens (human)
cAMP bindingRap guanine nucleotide exchange factor 4Homo sapiens (human)
protein-macromolecule adaptor activityRap guanine nucleotide exchange factor 4Homo sapiens (human)
small GTPase bindingRap guanine nucleotide exchange factor 4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (5)

Processvia Protein(s)Taxonomy
plasma membraneFree fatty acid receptor 2Homo sapiens (human)
cell projectionFree fatty acid receptor 2Homo sapiens (human)
plasma membraneFree fatty acid receptor 2Homo sapiens (human)
cytosolRap guanine nucleotide exchange factor 4Homo sapiens (human)
plasma membraneRap guanine nucleotide exchange factor 4Homo sapiens (human)
membraneRap guanine nucleotide exchange factor 4Homo sapiens (human)
hippocampal mossy fiber to CA3 synapseRap guanine nucleotide exchange factor 4Homo sapiens (human)
plasma membraneRap guanine nucleotide exchange factor 4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (16)

Assay IDTitleYearJournalArticle
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID454564Agonist activity at human FFA2 receptor expressed in CHO cells assessed as inhibition of forskolin-induced cAMP production relative to acetate2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
The first synthetic agonists of FFA2: Discovery and SAR of phenylacetamides as allosteric modulators.
AID454554Agonist activity at human FFA2 receptor expressed in CHO cells assessed as inhibition of forskolin-induced cAMP production2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
The first synthetic agonists of FFA2: Discovery and SAR of phenylacetamides as allosteric modulators.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (14.29)29.6817
2010's5 (71.43)24.3611
2020's1 (14.29)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.20

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.20 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index4.28 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.20)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]